Maraviroc failed to control progressive multifocal leukoencephalopathy-associated IRIS in a patient with advanced HIV infection

Case Reports in Medicine

Volumn 2014, Issue , 2014, Pages

  Rodríguez, Mónica ^a   Silva Sánchez, Fernando Antonio ^a   Luna Rivero, César ^a   Vega Barrientos, Ricardo ^a   Alvarado De La Barrera, Claudia ^a   Reyes Terán, Gustavo ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; AZITHROMYCIN; CLARITHROMYCIN; DEXAMETHASONE; EMTRICITABINE; ETHAMBUTOL; MARAVIROC; RITONAVIR; TENOFOVIR;

ADULT; ANOSOGNOSIA; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FATALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LUNG LAVAGE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECTUM BIOPSY;

EID: 84943427961     PISSN: 16879627     EISSN: 16879635     Source Type: Journal    
DOI: 10.1155/2014/381480     Document Type: Article

References (19)

1. E. Tavazzi,M. K.White, and K. Khalili, "Progressive multifocal leukoencephalopathy: clinical and molecular aspects," Reviews in Medical Virology, vol. 22, no. 1, pp. 18-32, 2012.
2. P. Cinque, I. J.Koralnik, S. Gerevini, J.M.Miro, andR.W. Price, "Progressive multifocal leukoencephalopathy in HIV-1 infection," The Lancet Infectious Diseases, vol. 9, no. 10, pp. 625-636, 2009.
3. G. Martin-Blondel, L. Cuzin, P. Delobel et al., "Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy- immune reconstitution inflammatory syndrome management?" AIDS, vol. 23, no. 18, pp. 2545-2546, 2009.
4. P. S. Giacomini, A. Rozenberg, I. Metz, D. Araujo, N. Arbour, and A. Bar-Or, "Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome,"The New England Journal of Medicine, vol. 370, no. 5, pp. 486-488, 2014.
5. International Network for the Study of HIV-Associated IRIS, General case definition, 2014, http://www.inshi.umn.edu/ definitions/General IRIS/home.html.
6. J. K. Lim, D. H. McDermott, A. Lisco et al., "CCR5 deficiency is a risk factor for early clinical manifestations of west nile virus infection but not for viral transmission," The Journal of Infectious Diseases, vol. 201, no. 2, pp. 178-185, 2010.
7. E. Kindberg, A. Mickiene, C. Ax et al., "A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis," Journal of Infectious Diseases, vol. 197, no. 2, pp. 266-269, 2008.
8. M. M. Lederman, A. Penn-Nicholson, M. Cho, and D. Mosier, "Biology of CCR5 and Its Role inHIV Infection and Treatment," Journal of the AmericanMedical Association, vol. 296, no. 7, pp. 815-826, 2006.
9. C. Antoniol, S. Jilek, M. Schluep et al., "Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management," Neurology, vol. 79, no. 23, pp. 2258-2264, 2012.
10. C. C. Chang, S. Omarjee, A. Lim et al., "Chemokine levels and chemokine receptor expression in the blood and the cerebro1 E. Tavazzi,M. K.White, and K. Khalili, "Progressive multifocal leukoencephalopathy: clinical and molecular aspects," Reviews in Medical Virology, vol. 22, no. 1, pp. 18-32, 2012.
11. P. Cinque, I. J.Koralnik, S. Gerevini, J.M.Miro, andR.W. Price, "Progressive multifocal leukoencephalopathy in HIV-1 infection," The Lancet Infectious Diseases, vol. 9, no. 10, pp. 625-636, 2009.
12. G. Martin-Blondel, L. Cuzin, P. Delobel et al., "Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy- immune reconstitution inflammatory syndrome management?" AIDS, vol. 23, no. 18, pp. 2545-2546, 2009.
13. P. S. Giacomini, A. Rozenberg, I. Metz, D. Araujo, N. Arbour, and A. Bar-Or, "Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome,"The New England Journal of Medicine, vol. 370, no. 5, pp. 486-488, 2014.
14. International Network for the Study of HIV-Associated IRIS, General case definition, 2014, http://www.inshi.umn.edu/ definitions/General IRIS/home.html.
15. J. K. Lim, D. H. McDermott, A. Lisco et al., "CCR5 deficiency is a risk factor for early clinical manifestations of west nile virus infection but not for viral transmission," The Journal of Infectious Diseases, vol. 201, no. 2, pp. 178-185, 2010.
16. E. Kindberg, A. Mickiene, C. Ax et al., "A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis," Journal of Infectious Diseases, vol. 197, no. 2, pp. 266-269, 2008.
17. M. M. Lederman, A. Penn-Nicholson, M. Cho, and D. Mosier, "Biology of CCR5 and Its Role inHIV Infection and Treatment," Journal of the AmericanMedical Association, vol. 296, no. 7, pp. 815-826, 2006.
18. C. Antoniol, S. Jilek, M. Schluep et al., "Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management," Neurology, vol. 79, no. 23, pp. 2258-2264, 2012.
19. C. C. Chang, S. Omarjee, A. Lim et al., "Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patientswith cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome," Journal of Infectious Diseases, vol. 208, no. 10, pp. 1604-1612, 2013.